( Merck & Co has cut the price of efavire...)Merck Cuts Price of Efavirenz for Developing Countries Again,Health

Merck & Co has cut the price of efavirenz 600mg tablets (Stocrin) for developing countries that qualify for its access programme//, the company announced yesterday.

It is the second price cut in a year, and crucially, it will make the branded version of efavirenz cheaper than a generic import in Thailand, where a compulsory license was recently issued to allow importation of efavirenz from India.

For least developed countries and medium human development index countries with an adult HIV prevalence of 1% or more, the price of Stocrin 600mg tablets is being reduced by 14.5%, to US$0.65 a day ($237.25 a year).

In medium HDI countries with an HIV prevalence of less than 1% the price of Stocrin is being reduced by 5.8%, to US$1.80 a day ($657 a year).

A company spokesman said that the company was able to cut the price as a result of identifying further manufacturing efficiencies.

The company says that as a result of its differential pricing policy around 500,000 patients in 76 developing countries were receiving Stocrin as part of their antiretroviral regimen.

Source-Bio-Bio Technology
'"/>




Page: 1
Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete